Epidermolysis Bullosa (EB)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Epidermolysis Bullosa (EB) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

RecruitingPhase 1/2

NCT06834035

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound…

United States8 participantsStarted 2025-08-04

Treatment: Immunoglobulin G

RecruitingPhase 2

NCT06594393

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in…

France, Greece, Spain32 participantsStarted 2026-01-30

Treatment: TCP-25 gel, Vehicle (placebo)

RecruitingNot Applicable

NCT07312513

Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® P…

The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Debrisoft® Duo, to collect safety data regarding expected adverse e…

Poland104 participantsStarted 2025-05-09

Treatment: two sided debridement pad, one sided debridment pad

RecruitingPhase 2

NCT06509984

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main quest…

France20 participantsStarted 2024-08-06

Treatment: Apremilast treatment

All recent trials (27 shown)

Not Yet RecruitingPhase 1/2

NCT07011589

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epi…

United States18 participantsStarted 2026-07

Treatment: Efgartigimod

Not Yet RecruitingPhase 4

NCT07240649

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially…

Location not specified100 participantsStarted 2026-08

Treatment: Hyperbaric oxygen treatment (HBOT), 100% Oxygen

Epidermolysis Bullosa (EB)

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® P…

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

All recent trials (27 shown)

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® P…

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

All recent trials (27 shown)

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over…

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated…

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Growth Hormone in EB

Topical Gentamicin Nonsense Suppression Therapy of EB

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof…

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis…

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients